Page 1

THE GENE THERAPY EXPLORER " During the first quarter of the year , CombiGene strengthened itself financially through a fully guaranteed rights issue of SEK 75 million in order to start the final and cost - intensive part of the preclinical phase of CG01 in accordance with plan . We have also strengthened the company's expertise and capacity regarding production , clinical studies , and gene therapy through three important new recruits . " Jan Nilsson CEO Interim Report January - March 2021 for CombiGene AB ( publ ) CombiGene